Proteasome inhibitors for the treatment of multiple myeloma
S Ito - Cancers, 2020 - mdpi.com
Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment
over the past decade. Many PIs are being developed and evaluated in the preclinical and …
over the past decade. Many PIs are being developed and evaluated in the preclinical and …
[HTML][HTML] Metformin beyond an anti-diabetic agent: A comprehensive and mechanistic review on its effects against natural and chemical toxins
A Malaekeh-Nikouei, S Shokri-Naei… - Biomedicine & …, 2023 - Elsevier
In addition to the anti-diabetic effect of metformin, a growing number of studies have shown
that metformin has some exciting properties, such as anti-oxidative capabilities, anticancer …
that metformin has some exciting properties, such as anti-oxidative capabilities, anticancer …
Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review
Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …
Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma
SPE Jayaweera… - Frontiers in …, 2021 - frontiersin.org
The proteasome is crucial for the degradation of intracellular proteins and plays an important
role in mediating a number of cell survival and progression events by controlling the levels …
role in mediating a number of cell survival and progression events by controlling the levels …
Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management
Abstract Purpose of Review Multiple myeloma is the second most common hematologic
malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in …
malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in …
Cardiotoxicity of anticancer drugs: molecular mechanisms, clinical management and innovative treatment
F Gao, T Xu, F Zang, Y Luo, D Pan - Drug Design, Development …, 2024 - Taylor & Francis
With the continuous refinement of therapeutic measures, the survival rate of tumor patients
has been improving year by year, while cardiovascular complications related to cancer …
has been improving year by year, while cardiovascular complications related to cancer …
Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway
Carfilzomib (CFZ) is a proteasome inhibitor approved for relapsed/refractory multiple
myeloma (MM) but its clinical use is limited by cardiovascular toxicity. The mechanisms of …
myeloma (MM) but its clinical use is limited by cardiovascular toxicity. The mechanisms of …
Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy
The treatment for multiple myeloma has advanced significantly over the past few decades.
Proteasome inhibitors have become the cornerstone of the treatment of multiple myeloma …
Proteasome inhibitors have become the cornerstone of the treatment of multiple myeloma …
Heart failure with targeted cancer therapies: mechanisms and cardioprotection
VS Hahn, KW Zhang, L Sun, V Narayan… - Circulation …, 2021 - Am Heart Assoc
Oncology has seen growing use of newly developed targeted therapies. Although this has
resulted in dramatic improvements in progression-free and overall survival, challenges in …
resulted in dramatic improvements in progression-free and overall survival, challenges in …
Obesity and multiple myeloma: Emerging mechanisms and perspectives
Obesity is a global pandemic that has been associated with the development of breast,
endometrial, large intestine, renal, esophageal, and pancreatic cancer. Obesity is also …
endometrial, large intestine, renal, esophageal, and pancreatic cancer. Obesity is also …